Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Diluted Average) (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Shares Outstanding (Diluted Average) readings, the most recent being $102.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 1.16% to $102.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $102.5 million, a 1.16% decrease, with the full-year FY2025 number at $102.5 million, down 1.16% from a year prior.
  • Shares Outstanding (Diluted Average) hit $102.5 million in Q4 2025 for Neurocrine Biosciences, roughly flat from $102.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $104.3 million in Q3 2024 to a low of $95.4 million in Q2 2022.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $100.4 million (2023), compared with a mean of $100.3 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 6.69% in 2024 and later decreased 2.7% in 2025.
  • Neurocrine Biosciences' Shares Outstanding (Diluted Average) stood at $97.9 million in 2021, then increased by 1.02% to $98.9 million in 2022, then increased by 2.12% to $101.0 million in 2023, then grew by 2.67% to $103.7 million in 2024, then dropped by 1.16% to $102.5 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $102.5 million (Q4 2025), $102.5 million (Q3 2025), and $101.0 million (Q2 2025) per Business Quant data.